SK Biopharm Signs Pharmaceutical Supply Contract Worth 1.9 Billion KRW

[Asia Economy Reporter Gong Byung-sun] SK Biopharm announced on the 15th that it has signed a pharmaceutical supply contract worth 1.9 billion KRW with its U.S. local subsidiary, SK Life Science, Inc., for the sale of the new epilepsy treatment drug Cenobamate in the U.S. market.

This corresponds to 7.23% of recent sales revenue.